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Purpose: To evaluate the efﬁcacy and safety of intravitreal bevacizumab (Avastin; Genentech, South San
Francisco, CA) in patients with neovascular age-related macular degeneration (nAMD) using 2 different treatment
regimens in which patients were assessed clinically at up to 12-week intervals.
Design: Randomized, controlled, noninferiority trial.
Participants: A total of 331 patients with nAMD.
Methods: Patients were treated with 1.25 mg intravitreal bevacizumab and followed up to 92 weeks. They
were randomized into 2 arms. All patients received 3 loading doses 4 weeks apart and thereafter were assessed
every 12 weeks until the end of the study. One arm received a routine treatment at each 12-week assessment,
and the other arm was treated at these assessments on an as-needed basis. After the loading doses, patients in
either arm who showed signs of disease activity had an additional assessment after 6 weeks and at that visit had
top-up treatments on an as-needed basis.
Main Outcome Measures: Mean best-corrected visual acuity (BCVA) at 92 weeks.
Results: At 92 weeks, patients who had treatments every 12 weeks had superior BCVA to those treated on
an as-needed basis every 12 weeks (P ¼ 0.008), with the regular treatment arm gaining a mean BCVA of 5.5
letters and the as-needed treatment arm gaining 0.6 letters. The regular treatment arm of the study showed
signiﬁcantly improved outcomes with respect to 5-, 10-, and 15-letter changes in BCVA from baseline compared
with the as-needed treatment arm, as well as superior reading speed. In patients who completed the study, up to
but not including week 92, the mean number of treatments was 10.8 for the regular treatment arm and 9.1 for the
as-needed treatment arm.
Conclusions: A treatment regimen with regular bevacizumab injections every 12 weeks after loading doses
supplemented with as-needed top-up treatments produced a stable improvement in BCVA from baseline. The
improvement in BCVA was broadly similar to that obtained in other studies using anti-vascular endothelial growth
factor drugs with more frequent assessments and treatments. Ophthalmology 2015;122:1348-1355 ª 2015 by the
American Academy of Ophthalmology. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
*Supplemental material is available at www.aaojournal.org.Neovascular age-related macular degeneration (nAMD) is
one of the leading causes of blindness in the western world,1
and vascular endothelial growth factor (VEGF) is an
important agent in its pathogenesis. In 2006, landmark
trials demonstrated a profound impact of monthly
injections of the anti-VEGF agent ranibizumab (Lucentis;
Genentech, South San Francisco, CA) on patients with
nAMD, heralding a surge of interest in the treatment of this
condition and in anti-VEGF agents.2,3 Aﬂibercept (Eylea;1348  2015 by the American Academy of Ophthalmology
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(http://creativecommons.org/licenses/by-nc-nd/4.0/). Published by Elsevier IncBayer/Regeneron, Tarrytown, NY) is a more recent anti-
VEGF therapeutic with a higher afﬁnity for VEGF, and its
use in clinical trials has demonstrated noninferiority in
visual outcomes to monthly ranibizumab injections, despite
only being injected every 2 months after the ﬁrst loading
dose phase.4 As well as ranibizumab and aﬂibercept, many
ophthalmologists globally use bevacizumab (Avastin,
Genentech) off-label, which is a less-expensive anti-VEGF
alternative5 and has demonstrated noninferiority of visual.
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controlled trials.6e9
Delivery regimens for each of these agents varies; treat-
ment by monthly injections has been used as a gold standard
strategy for visual outcomes in comparison trials, but is
rarely followed in clinical practice, with most physicians
opting for less frequent injection regimens using as-needed
treatments, or regimens whereby treatment intervals are
varied according to disease activity. Service providers and
clinicians need to consider economic, capacity, and conve-
nience factors, as well as clinical efﬁcacy and safety, when
deciding on optimal treatments and treatment regimens for
their patients. Thus, there is a need for pragmatic trials that
compare alternative and less-intense treatment schedules.
The Greater Manchester Avastin for Neovascularisation
(GMAN) study is such a trial, designed to compare the
efﬁcacy of a pro re nata (PRN) and regular (or ROUTINE)
treatment regimen of bevacizumab for nAMD. Both study
arms began with an injection every 4 weeks for the ﬁrst
12 weeks and thereafter had evaluations every 12 weeks,
with an option of an intermediate 6-week evaluation and
treatment if there were signs of disease activity. Patients in
the ROUTINE arm of this study received regular injections
every 12 weeks at the scheduled visits, and patients in the
PRN arm were treated at these scheduled visits on an as-
needed basis when signs of disease activity were present.
The study treatment regimens assessed patients on a less
frequent basis than typically used in current practice.
Methods
This was a single-center (Manchester Royal Eye Hospital, Man-
chester, UK), randomized, noninferiority trial comparing
2 different treatment regimens using bevacizumab for nAMD. It
took place between February 2008 and May 2013. The trial was
approved by a UK National Health Service Research Ethics
Committee (07/H0206/57) and the UK government Medicines and
Healthcare Products Regulatory Agency. It was registered with
Current Controlled Trials (ISRCTN34221234) and the European
Clinical Trials database (EudraCT number 2007-003853-97).
Full inclusion and exclusion criteria are listed in Table 1
(available at www.aaojournal.org). In brief, patients aged more
than 50 years with a diagnosis of nAMD and a best-corrected
visual acuity (BCVA) of logarithm of the minimum angle of res-
olution 0.3 to 1.2 were recruited. Patients were excluded if the
lesion showed signs of >50% ﬁbrosis, hemorrhage, or serous
pigment epithelial detachment. Patients with a medical history of
myocardial infarction, cardiovascular accident, or gastrointestinal
perforation were excluded when the trial commenced. However, as
more evidence emerged suggesting a low systemic risk from the
intravitreal use of anti-VEGF drugs, the protocol was amended so
that myocardial infarction and gastrointestinal perforation were not
used as exclusion criteria, and only patients with a history of
cerebrovascular accident within 6 months were excluded.
Participants were randomly assigned to 1 of 2 treatment arms.
Computer-generated allocation lists were drawn up by the trial
statistician using block randomization with a variable block size.
Randomization was performed after patients had been successfully
screened and recruited into the trial.
One eye of each of the recruited patients was included in the
study. The patients in the study were treated with intravitreal in-
jections of 1.25 mg of bevacizumab. The bevacizumab used in thestudy was compounded by the pharmacy at the Royal Liverpool
and Broadgreen University Hospitals NHS Trust (Liverpool, UK).
The details of how this bevacizumab was prepared have been
described.8
The assessments that were undertaken at each clinic visit are
summarized in Table 2 (available at www.aaojournal.org). The
optometrists who measured BCVA, reading speed, and contrast
sensitivity were masked to the study arm; patients, treating
clinicians, and other staff involved in the study were not masked.
The BCVA was measured using Early Treatment of Diabetic
Retinopathy Study charts (Precision Vision, LaSalle, IL) at 2 m;
2 measurements were taken at each visit, and the result was
averaged. Contrast sensitivity was determined with Pelli-Robson
charts at 1 m as described previously.10 Near vision visual
function was measured using MNREAD Acuity Charts
(University of Minnesota) at 40 cm with controlled lighting and
optimized refraction, following the manufacturer’s protocol.11
This enabled calculation and graphical determination of critical
print size, reading acuity, and maximum reading speed. Reading
acuity (the smallest print size read correctly) was deﬁned as
1.4  (sentences read  0.1) þ (number of words read
incorrectly  0.01). Critical print size was the size of print at
which reading speed ﬁrst starts to decline from its maximum.
Maximum reading speed was measured by the maximum number
of words read per minute. These last 2 measurements were
determined by plotting the time taken to read each sentence
against sentence print size.
Central 1-mm macular thickness was measured by automated
analysis on a Cirrus (Carl Zeiss, Oberkochen, Germany) optical
coherence tomography (OCT) machine. Lesion morphology on
recruitment to the study was assessed by the treating clinician after
ﬂuorescein angiography (FFA).
The study had PRN and ROUTINE treatment arms (Fig 1). The
treatment regimen was the same in both study arms up to week 20;
thereafter, the 2 arms differed. All patients received injections of
bevacizumab at baseline and then at weeks 4 and 8. After week
8, all patients were evaluated every 12 weeks until the end of the
study at week 92. From week 20 onward, patients in the PRN
arm received treatment at each 12-week evaluation on an as-
needed basis. Treatments were given if the lesion was deemed to
be active by 1 or more of the following criteria: loss of 5 letters of
vision since last visit, presence of subretinal ﬂuid, increase in
central retinal thickness of 100 mm from thinnest recorded
measurement, increase in lesion size by FFA, and new subretinal
blood at edge of lesion. Treating clinicians were also given the
option of giving bevacizumab treatments for other reasons, and
these were recorded. From week 20 onward, patients in the
ROUTINE arm received a regular injection of bevacizumab at
12-week intervals, irrespective of clinical signs. Patients in both
arms of the study from week 8 onward were brought back for an
interim assessment 6 weeks later if they had lost 5 letters of
vision at the last scheduled visit, had subretinal ﬂuid present, or
had increased central retinal thickness of 100 mm from the thinnest
measurement. At the interim visit, the assessing clinician gave a
top-up treatment if any of these signs were still present.
The protocol included an assessment of results at week 44 by
the trial Data Monitoring and Ethics Committee to determine
whether the study demonstrated sufﬁcient efﬁcacy and safety to
continue into a second year. The Committee reported to the Trial
Steering Committee that the study showed adequate efﬁcacy and
safety to proceed, but did not reveal the results of this interim
analysis to the study investigators.
There was a protocol change during the study. In the initial
protocol, patients who were in the ROUTINE arm, while being
maintained in this arm, were switched to an as-needed treatment1349
Figure 1. Overview of assessment and treatment schedules for the 2 study arms. PRN ¼ pro re nata.
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1 year. The protocol was changed during the study, and subse-
quently all patients in the ROUTINE arm were scheduled to have
bevacizumab treatment at 12-week intervals whether there was
disease activity or not. Before modifying the protocol, 9 patients in
the ROUTINE arm who had had no disease activity for 12 months
were converted to as-needed treatments, resulting in 17 treatments
not being given to patients in the ROUTINE arm.
The primary end point outcome measure was mean BCVA at
92 weeks, with the trial designed to demonstrate that the PRN arm
was not inferior to the ROUTINE arm with a noninferiority
margin set at 5 letters. Prespeciﬁed secondary objectives
included comparing change in mean visual acuity from baseline to
92 weeks and the percentages of patients who had a change in
visual acuity from baseline of 5, 10, or 15 letters. Other
prespeciﬁed objectives included comparing contrast sensitivity,
reading speed, and central macular thickness between the 2 arms
at 92 weeks. The initial standard deviation of BCVA was esti-
mated on the basis of pilot data to be 20, but after a masked re-
view of the ﬁrst 50 patients treated and follow-up for 5 months,
this was found to be 12. This allowed for a noninferiority margin
of 4 to 5 letters at 90% power for the sample size planned for the
study (165 in each arm).
The primary analysis used a mixed model that assumes that the
missing outcomes are “missing at random.” All visits 20 weeks
(i.e., after treatments diverge) were included in the model with
baseline outcome and baseline by visit interactions included as
continuous variables, and visit and visit by arm interactions being
included as factor variables. Because an unstructured covariance
matrix was overspeciﬁed, a number of alternatives were explored
and a banded structure was selected on the basis of the Akaike
information criterion, which allowed for correlations between
outcomes from the 4 visits for either group. Exploratory analyses
conﬁrmed that the results were not sensitive to the choice of
correlation structure. A 2-sided 95% conﬁdence interval (CI) es-
timate of the treatment effect was constructed from the model
estimates to be used for interpretation of superiority or non-
inferiority. Numbers with positive or negative responses using
alternative thresholds were tabulated and informally compared
between groups using Fisher exact tests (i.e., no covariate
adjustment). Although, given the design as a noninferiority study,
intention-to-treat (all visits for all randomized participants) and
per-protocol (patients who attended at least 75% of the scheduled
treatment sessions) analyses were prespeciﬁed, as clear superior-
ity was demonstrated, we present only the intention-to-treat re-
sults in this article.1350Results
A total of 331 patients were recruited to the study and randomized
with 166 entering the PRN arm and 165 entering the ROUTINE
arm (Fig 2). There were no substantial imbalances in the ocular or
demographic characteristics between the 2 arms of the study
(Table 3). During the study, 48 patients (14.5%) withdrew (26 in
the PRN arm; 22 in the ROUTINE arm); consequently, 140
patients completed the study in the PRN arm, and 143 patients
completed the study in the ROUTINE arm. The reasons for
withdrawal included death/systemic illness in 33 patients,
withdrawal of consent in 4 patients, loss to follow-up/moved out
of area in 10 patients, and unable to assess visual acuity in 1 patient
(Fig 2). Four patients, 2 per arm, were switched to ranibizumab
during the study and then monitored on a 4-week basis. One pa-
tient in the PRN arm was switched to monthly assessments because
of poor treatment response, and 1 patient in the ROUTINE arm had
a retinal detachment and subsequently was treated on a PRN basis.
No protocol deviations were recorded where patients met the
criteria for as-needed treatment, but the treatment was not given.
Other protocol deviations included 14 missed patient visits or
treatments (6 in the PRN arm, 8 in the ROUTINE arm) and 128
patient visits (3.4% total; 3.7% PRN arm; 3.0% ROUTINE arm)
taking place outside 1 week of the scheduled date in the ﬁrst
3 monthly assessments or 2 weeks of the 12-week assessments.
The number of patients attending at each visit and the propor-
tion treated are summarized in Table 4 (available at
www.aaojournal.org). The proportion of patients in the PRN arm
from week 20 onward who were treated at each 12-week assess-
ment varied between 60.5% and 70.5% (mean, 65.4%). The pro-
portion in the PRN arm who attended for additional interim
assessments was between 38.0% and 41.1% (mean, 39.0%), and the
proportion who were treated at these interim assessments was be-
tween 24.7% and 31.3% (mean, 27.7%). In the ROUTINE arm,
between 23.8% and 44.4% (mean, 30.6%) of patients attended
additional interim assessments at any particular time point, and at
those interim assessments, between 17.5% and 33.8% (mean 23.2%)
were treated. The reasons given for treating at scheduled visits in the
PRN arm or at interim visits in either arm were similar (Table 5,
available at www.aaojournal.org). The most common primary
reasons were the presence of subretinal ﬂuid (52% and 58% in the
PRN and ROUTINE arms, respectively) and a decrease of 5
letters of vision (30% and 21% in the PRN and ROUTINE arms,
respectively). Increased lesion size on FFA and new subretinal
hemorrhage were given as reasons on less than 4% of occasions.
On 6% and 13% of occasions, “other reasons” for treatment were
Figure 2. Flow diagram of patient participation. PRN ¼ pro re nata.
Table 3. Patient Demographics and Baseline Characteristics
PRN Arm Routine Arm
Age, yrs
Median (IQR) 80 (75e86) 80 (75e85)
Gender
Female 62% 60%
Male 38% 40%
Ethnicity
British/Irish white 97% 96.4%
Other white 2.4% 3%
Indian 0.6% 0%
Caribbean 0% 0.6%
BP systolic (mmHg)
Median (IQR) 148 (135e160) 149 (134e161)
BP diastolic (mmHg)
Median (IQR) 75.5 (69e82) 77 (70e83)
Intraocular pressure (mmHg)
Median (IQR) 16.0 (15.0e18.0) 18.0 (15.0e20.0)
Lesion
Predominantly classic 46% 59%
Minimally classic 19% 19%
Occult 34% 22%
logMAR study eye
Median (IQR) 52.5 (44.0e64.0) 54.0 (40.0e63.0)
logMAR fellow eye
Median (IQR) 68.0 (25.0e80.0) 68.0 (30.8e78.8)
Retinal thickness, mm (OCT)
Median (IQR) 355 (310e464) 369 (326e488)
BP ¼ blood pressure; IQR ¼ interquartile range; logMAR ¼ logarithm of
the minimum angle of resolution; OCT ¼ optical coherence tomography;
PRN ¼ pro re nata.
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retinal thickness that had not reached 100 mm greater than the
thinnest measurement. In total, the mean number of treatments for
patients completing the study was 10.8 for the ROUTINE arm and
9.1 for the PRN arm, excluding the last visit at weeks 92.
The primary outcome measure was BCVA at 92 weeks. There
was no signiﬁcant difference at week 20 (up to week 20, the
treatment regimen was identical in both arms). At the end of the
study (week 92), the ROUTINE arm was superior to the PRN arm
(P¼ 0.008) (Table6).Comparedwith baseline, the patients in thePRN
arm had a mean gain in visual acuity of 0.6 (95% CI, 2.0 to 3.1)
letters, whereas the ROUTINE arm had a mean gain of 5.5
(95% CI, 2.9e8.0) letters at 92 weeks; the change in visual
acuity over time is shown in Figure 3. By comparing the
proportion of patients who gained or lost 5, 10, or 15 letters
of vision over the course of the study, the ROUTINE arm
was superior to the PRN arm by all measures (Fig 4). A
higher number of patients in the PRN arm (22/168) lost vision
of 20 letters or more between visits at some point during the
study compared with the ROUTINE arm (8/165). This
difference was statistically signiﬁcant (P ¼ 0.008, Fisher test).
Other outcome measures in the study included contrast sensi-
tivity, reading speed, and central macular thickness measure using
OCT. At 92 weeks, reading speed was superior in the ROUTINE
arm compared with the PRN arm, but there was no signiﬁcant
difference in contrast sensitivity or central macular thickness be-
tween the 2 arms (Table 6).
Ocular adverse events (AEs) are summarized in Table 7 (available
at www.aaojournal.org). One patient had a retinal detachment in the
study eye, and 1 patient had a vitreous hemorrhage; both of these
AEs were deemed to be probably related to the injection procedure.
Five patients developed uveitis during the study. In 3 of these, itwas unilateral to the study eye and deemed to be probably related to
bevacizumab treatment; 2 of these patients were switched to
ranibizumab, and 1 of these patients was monitored but did not
receive any further treatments in the study. In 2 other patients, the
uveitis was bilateral and not thought to be related to the study drug.
Other signiﬁcant ocular AEs in the study eye included 2 retinal
pigment epithelial tears in study eyes, and 24 patients (7.2%)
underwent cataract surgery during the study; they were equally
distributed between the 2 study arms.
A total of 113 nonocular systemic serious AEs were recorded
during the study: 63 in the ROUTINE arm and 50 in the PRN arm
(Table 7, available at www.aaojournal.org). These were classiﬁed
as previously described.7 There were 22 deaths in total, with
5 (1.5%) due to an arterial thrombotic event and 3 (1%) due to
heart failure. There were no unexpected safety signals in the study.Discussion
Although this was designed as a noninferiority trial, it
demonstrated that after 3 initial monthly doses of bev-
acizumab and 92 weeks of follow-up, a treatment regimen
with ﬁxed 12-week dosing (ROUTINE arm) was superior to
12-week, as-needed treatments (PRN arm), with both arms
having additional as-needed interim treatments (Fig 1). At
92 weeks, the ROUTINE arm gained a mean visual acuity
of 5.5 letters from baseline, whereas the PRN arm gained
0.6 letters. The PRN arm treatment regimen produced
relatively poor results when compared with other trials1351
Table 6. Primary and Secondary Outcome Measures
Mean Best-Corrected Visual Acuity at Baseline, Week 20, and Week 92
Outcome
Visit
(Week) PRN Mean (SD) Routine Mean (SD) Effect (CI) Routine - PRN P Value
BCVA (logMAR) 0 52.7 (12.7) 51.5 (13.5)
20 56.1 (16.6) 56.6 (16.3) 1.7 (0.82 to 4.2) 0.187
92 52.8 (19.4) 57.2 (17.6) 4.8 (1.2e8.3) 0.008
Contrast Sensitivity, Reading Speed, and Central Macular Thickness at Baseline and Week 92
Outcome Week PRN Mean (SD) Routine Mean (SD) Effect (CI) (Routine-PRN) P Value
Contrast
sensitivity
(Pelli-Robson)
0 21.7 (5.9) 21.6 (5.5)
92 20.5 (6.8) 21.8 (5.5) 1.2 (0.048 to 2.4) 0.060
Reading speed 0 120.7 (65.9) 106.7 (67.0)
92 118.1 (70.3) 130.3 (68.2) 19.4 (5.1e33.8) 0.008
Central macular
thickness (OCT)
0 386.5 (113.2) 394.7 (109.7)
92 272.4 (82.5) 263.9 (71.2) 8.5 (26.5 to 9.4) 0.35
BCVA ¼ best-corrected visual acuity; CI ¼ conﬁdence interval; logMAR ¼ logarithm of the minimum angle of resolution; OCT ¼ optical coherence
tomography; PRN ¼ pro re nata; SD ¼ standard deviation.
Ophthalmology Volume 122, Number 7, July 2015using bevacizumab over a similar time-frame on an as-
needed basis, but with more frequent assessments.7,9
Smaller studies published before this trial commencing in
February 2008 suggested that intravitreal bevacizumabmay be
an effective treatment for nAMD.12e14 Since then, 2 large,
randomized controlled trials, the Comparison of AMD Treat-
ment Trials (CATT) and Inhibition of VEGF in Age-relatedFigure 3. Change in visual acuity from baseline over course of study (error
bars show standard errors of the unadjusted difference from baseline).
Vertical line indicates the 20-week time point before which the 2 arms
were treated identically. logMAR ¼ logarithm of the minimum angle of
resolution; PRN ¼ pro re nata.
1352choroidal Neovascularization (IVAN) studies, have demon-
strated noninferiority between ranibizumab and bevacizumab,
whether given in routine monthly doses or using as-needed
treatment schedules; both studies had 4-week assessments.7e9
The pivotal studies demonstrating the efﬁcacy of rani-
bizumab (Anti-VEGF Antibody for the Treatment of
Predominantly Classic Choroidal Neovascularization in
AMD [ANCHOR] and Minimally Classic/Occult Trial of
the Anti-VEGF Antibody Ranibizumab in the Treatment of
Neovascular AMD [MARINA]) used 4-week assessments/
treatments, and this is currently common practice,2,3 albeit
other studies have demonstrated that alternative regimens
can be effective, such as treat-and-extend.15,16 Hospital
visits every 4 weeks can be a major burden for patients, their
caregivers, and healthcare systems. The GMAN trial was
undertaken to investigate less frequent assessment intervals
using bevacizumab (1.25 mg); an assessment interval of
12 weeks was chosen, but adding an additional interim visit
at 6 weeks for patients showing evidence of disease activity.
The maximum number of visits in the study protocol was
17, and the maximum number of treatments was 16. In the
PRN arm, the mean number of visits for patients who
completed the study was 12.4 (mean number of treatments,
9.1). In the ROUTINE arm, the mean number of patient
visits was 11.9 (mean number of treatments, 10.8). By
comparison, in the CATT study over 104 weeks, the patients
treated with the as-needed schedule received 14.1 injections
of bevacizumab from a maximum of 26 possible injections
(27 visits).7 Over 92 weeks, patients being treated with
aﬂibercept would expect to attend on 13 occasions.
Other studies have used ranibizumab with regular treat-
ment regimens every 3 months. The year 1 results of the
PIER study were published the same month that this study
commenced.17 In the PIER study, after 3 loading doses,
ranibizumab was administered at 3-month intervals. After
1 year, the BCVA for patients receiving 0.3 mg ranibizumab
was 1.6 letters from baseline, and after 2 years, BCVA
Figure 4. Change in best-corrected visual acuity (BCVA) from baseline of
5, 10, or 15 letters at 92 weeks. The ROUTINE arm demonstrated
superiority to the pro re nata (PRN) arm in all 3 measures: 5 letters, P ¼
0.005; 10 letters, P ¼ 0.030; 15 letters, P ¼ 0.010 (Fisher exact test).
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arm of the GMAN study compares favorably with a
5.5-letter gain from baseline over 92 weeks. The EXCITE
study lasted 12 months and compared monthly versus
quarterly dosing with ranibizumab.19 In this study, monthly
dosing was superior to quarterly dosing, and the gain in
visual acuity in the monthly dosing was 8.0 letters
compared with 4.0 letters for quarterly dosing with 0.3 mg
of ranibizumab. In the GMAN study, the ROUTINE arm
at the equivalent time point (56 weeks) had a gain in
vision of 7.0 (1.2) letters. Therefore, with the caveat that
cross-study comparisons have limitations, the ROUTINE
treatment arm of the GMAN study did seem to produce
better results than other 3 monthly dosing studies.
We believe that the main reason for the better results in
the ROUTINE arm of the GMAN study than the PIER and
EXCITE studies is the incorporation of the interim top-up
treatments when there was disease activity. Treatment in-
tervals of 3 months are likely to be too long in the presence
of active disease. This also provides an explanation as to
why the ROUTINE arm was superior to the PRN arm of the
GMAN study despite there being only a modest difference
in the mean number of treatments (10.8 vs. 9.1) because
patients were not treated soon enough after reactivation of
disease in the PRN arm. Our approach in the ROUTINE arm
combines the beneﬁts of regular treatments to stabilize
disease (without risking overtreatment) and relatively long
follow-up times, with additional top-up treatment to allow
treatment to be tailored to individual patients.
A second potential reason why the results of the
ROUTINE arm of the GMAN trial are better than those
from the PIER or EXCITE studies is that bevacizumab has a
longer half-life in the vitreous than ranibizumab.20,21
However, ranibizumab does have higher binding afﬁnity
and being a smaller molecule has the potential for greater
penetration of the retina.21,22 A further possible reason is
that the GMAN study protocol excluded lesions showing
serous pigment epithelial detachment >50% of the lesion.This characteristic is associated with lesions that are harder
to treat, such as idiopathic polypoidal choroidal vasculop-
athy and retinal angiomatous proliferation.
The GMAN study recorded the basis of as-needed
treatment decisions. The presence of subretinal ﬂuid was
the primary reason given on more than 50% of occasions. A
decrease in BCVA of 5 letters was the second most
common reason, although this is not a reliable method given
the variability of repeat responses observed,23,24 and in
routine clinical practice, this variability may be higher. The
third most common reason was increased central retinal
thickness of >100 mm from the thinnest measurement. This
criterion was also used in earlier studies of PRN ranibizu-
mab and could be 1 reason for inferior results versus
monthly ranibizumab.25 In the GMAN trial, investigators
were allowed the ﬂexibility of giving “other reasons” as
an indication for treatment, and most commonly the
reason given was an increase in retinal thickness of less
than 100 mm. In more recent studies, such as the CATT
study, a “zero tolerance” of ﬂuid approach was used to
judge disease activity. The presence of new subretinal
hemorrhage or increased lesion size on FFA was rarely
given as a reason for treatment in the GMAN study,
suggesting that these are not important criteria for making
re-treatment decisions.
The GMAN study protocol had predeﬁned re-treatment
criteria for as-needed treatments, which were adhered to
throughout the study. When intraretinal ﬂuid was used as a
re-treatment criterion, the protocol dictated that re-treatment
should be given only if intraretinal ﬂuid increased central
retinal thickness by 100 mm from the thinnest recorded
measurement. In other recent studies such as CATT, the
presence of any intraretinal ﬂuid was used as a re-treatment
criterion. If we had used this criterion in the GMAN study,
the outcomes, especially in the PRN arm, might have been
improved, and there may have been less of a difference
between the study arms in outcomes. However, the differ-
ence between these trial protocols was partially offset by
allowing GMAN investigators to treat at their own discre-
tion if they thought the disease was active, but did not meet
re-treatment criteria: The presence of intraretinal ﬂuid that
was less than 100 mm from the thinnest recorded measure-
ment was the most commonly given reason for doing this.
Study Strengths and Limitations
This study was not powered to investigate safety and can
only provide limited safety information because bev-
acizumab was used in both arms. However, no new safety
signals emerged from the study. An important caveat is that
the bevacizumab used in this study was provided by a
compounding pharmacy that aliquoted and dispensed the
drug, adhering to UK Medicines and Healthcare products
Regulatory Agency standards. When less rigorous standards
have been applied, serious AEs including endophthalmitis
have emerged.26,27
A major advantage of bevacizumab is that it is more cost-
effective than the licensed drugs ranibizumab and
aﬂibercept,28e30 and where there are no regulatory hurdles
to its use, it provides an alternative therapeutic approach.1353
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ROUTINE arm of this study with regular 12-week injections
and interim treatments where necessary, could make bev-
acizumab even more cost-effective, and at the same time
decrease the burden on patients and healthcare professionals
of more frequent assessments and treatments.
A strength of the GMAN trial is its pragmatic design,
with patients in the study being treated alongside nonstudy
patients in a routine hospital setting. Limitations include the
following: lack of a monthly assessment arm (which is
regarded as the gold standard for comparative studies); not
all lesion types were included; and because of ﬁnancial
constraints, there was no independent validation of clinical
observations, angiography images, and automated OCT
measurements by an external reading center. Although the
PRN treatment arm produced inferior results, this study
provides evidence that the ROUTINE protocol of regular
treatments at 12-week intervals with bevacizumab and
interim treatments when necessary is an effective way to
manage nAMD.
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